Royalty Pharma Plc

( )
RPRX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
PFEPfizer Inc. -0.42%38.170.9%$1158.92m
JNJJohnson & Johnson -1.13%147.970.7%$862.62m
MRKMerck & Co., Inc. 1.09%83.580.7%$652.14m
BMYBristol-Myers Squibb Co. -0.63%63.241.0%$639.81m
ABBVAbbVie, Inc. -0.83%94.721.9%$619.79m
AZNAstraZeneca Plc -0.85%55.811.2%$561.08m
LLYEli Lilly & Co. -0.90%150.441.1%$406.70m
NVSNovartis AG 0.52%85.370.2%$149.02m
GSKGlaxoSmithKline Plc -1.15%41.190.2%$136.11m
MISTMilestone Pharmaceuticals, Inc. -0.68%8.740.0%$120.06m
OPKOPKO Health, Inc. 2.86%4.8611.2%$116.06m
NVONovo Nordisk A/S -0.31%66.880.1%$71.85m
RGENRepligen Corp. 2.33%146.267.1%$69.88m
PRNBPrincipia Biopharma, Inc. 5.11%91.800.0%$59.25m
SNYSanofi -0.81%51.370.2%$57.17m

Company Profile

Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The firm's portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Symdeko and Trikafta, and four development-stage product candidates. It focuses on acquiring royalty-generating products segment. The firm invests in biopharmaceutical products. The company was founded by Pablo Gerardo Legorreta in 1996 and is headquartered in New York, NY.